Shots:  

• The company has initiated a controlled launch of the ACURATE neo2 Aortic Valve System in the EU. The ACURATE neo2 valve system has expanded its indication for patients with aortic stenosis with no specified age or risk level
• The new system uses TAVI technology and builds on the clinical performance of the original ACURATE neo platform. The new system has demonstrated lower PVL rates in the ACURATE neo2 CE-Mark study compared to its current generation ACURATE neo valve
• At 30 days & 1yr after implantation- 97% & 97.5% of patients experienced ≤ no/trace or mild PVL- 3.0% & 2.5% of patients experienced moderate PVL and 0% of patients experienced severe PVL respectively. The new system has received CE mark in Apr’2020

­ Ref: Boston Scientific  | Image: Boston Scientific